A Phase 3 interventional study of E/C/F/TAF in HIV and HIV Infections, sponsored by Gilead Sciences. Completed at 70 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-02.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing elvitegravir in HIV Infections — none open to participants now, none under way, none of them phase 3. elvitegravir · HIV Infections.
Among the 11 studies testing elvitegravir in HIV Infections, this one is the 6th largest by enrollment, is one of 7 that started in 2013, is one of 7 in phase 3, and was the 7th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →None of the 11 studies testing elvitegravir in HIV Infections is open now. The open studies under HIV Infections, anywhere →
elvitegravir: first FDA approval 2012 (STRIBILD), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 9
First in 2007; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 252 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 252 across the 11 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
84 studies in HIV Infections by Gilead Sciences: 2 open now, 8 under way, 4 of them phase 3. Of 71 finished, 28 (39%) have results posted.
Among the 84 studies in HIV Infections by Gilead Sciences, this one is the 26th largest by enrollment of the 72 interventional ones that give a count, is one of 10 that started in 2013, is one of 26 in phase 3, and was the 69th registered.
Gilead Sciences’s HIV Infections studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing elvitegravir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 84 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effect of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) tablet on renal parameters at Week 24 in treatment-naive and treatment-experienced HIV-positive, adults with mild to moderate renal impairment.
Key Inclusion Criteria:
Cohort 1 (treatment-experienced switch)
Cohort 2 (treatment-naive)
All Cohorts:
All individuals must meet all of the following inclusion criteria to be eligible for participation in this study:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive E/C/F/TAF for 144 weeks. Following Week 144, in countries where E/C/F/TAF is not available (except for the United Kingdom), participants will be given the option to continue in the study and receive E/C/F/TAF for another 48 weeks, or until the product becomes available through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever comes first.
Drug: E/C/F/TAF
Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
Also known as: Genvoya®
Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24
eGFR is a measurement of the kidney's ability to filter blood.
Time frame: Baseline; Week 24
Change From Baseline in eGFR Calculated by the Chronic Kidney Disease Epidemiology Collaboration Method Based on Cystatin C (eGFR_CKD-EPI,cysC) at Week 24
eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,cysC method is adjusted for age and sex.
Time frame: Baseline; Week 24
Change From Baseline in eGFR Calculated by the CKD-EPI Method Based on Serum Creatinine (eGFR_CKD-EPI,Creatinine) at Week 24
eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,creatinine method is adjusted for age, race, and sex.
Time frame: Baseline; Week 24
Change From Baseline in Actual GFR (aGFR) of E/C/F/TAF for Participants Enrolled in the PK/PD Substudy
aGFR was directly measured using iohexol plasma clearance (CLiohexol).
Time frame: Baseline; Week 2, 4, or 8; Week 24
Percent Change From Baseline in C-type Collagen Sequence (CTX) at Weeks 24 and 48
CTX is a biomarker of bone turnover.
Time frame: Baseline; Weeks 24 and 48
Percent Change From Baseline in Procollagen Type 1 N-terminal Propeptide (P1NP) at Weeks 24 and 48
P1NP is a biomarker of bone turnover.
Time frame: Baseline; Weeks 24 and 48
Percent Change From Baseline in Retinol Binding Protein (RBP) to Creatinine Ratio (μg/g) at Weeks 24, 48, 96, and 144
Urine RBP is a renal biomarker which is used to evaluate drug-induced kidney injury.
Time frame: Baseline; Weeks 24, 48, 96, and 144
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio (μg/g) at Weeks 24, 48, 96, and 144
Urine beta-2-microglobulin is a renal biomarker which is used to evaluate drug-induced kidney injury.
Time frame: Baseline; Weeks 24, 48, 96, and 144
Percentage of Participants Experiencing Adverse Events or Graded Laboratory Abnormalities
Adverse events (AEs) and graded laboratory abnormalities occurring during the E/C/F/TAF treatment period were summarized across the participant population. A participant was counted once if they had a qualifying event.
Time frame: Baseline up to Week 240 plus 30 days
Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Weeks 24, 48, 96, and 144
The percentage of participants achieving HIV-1 RNA \< 50 Copies/mL at Weeks 24, 48, 96, and 144 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Weeks 24, 48, 96, and 144
Pharmacokinetic (PK) Parameter: Cmax of TAF
Cmax is defined as the maximum concentration of drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
PK Parameter: Tmax of TAF
Tmax is defined as the time of Cmax. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
PK Parameter: Clast of TAF
Clast is defined as the last observable concentration of drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
PK Parameter: Tlast of TAF
Tlast is defined as the time of Clast. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
PK Parameter: λz of TAF
λz is defined as the terminal elimination rate constant. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
PK Parameter: AUCtau of TAF
AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
PK Parameter: t1/2 of TAF
t1/2 is defined as the estimate of the terminal elimination half-life of the drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
PK Parameter: AUCtau of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cell (PBMC) for Participants Enrolled in PK/PD Sub-study
TFV-DP is an active phosphorylated metabolite of tenofovir alafenamide. AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
Time frame: Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose
Change From Baseline in the eGFR_CG at Weeks 48, 96, and 144
eGFR is a measurement of the kidney's ability to filter blood.
Time frame: Baseline; Weeks 48, 96, and 144
Change From Baseline in eGFR_CKD-EPI,cysC at Weeks 48, 96, and 144
eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,cysC method is adjusted for age and sex.
Time frame: Baseline; Weeks 48, 96, and 144
Change From Baseline in eGFR_CKD-EPI,Creatinine at Weeks 48, 96, and 144
eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,creatinine method is adjusted for age, race, and sex.
Time frame: Baseline; Weeks 48, 96, and 144
Participants were enrolled at study sites in North America, Australia, Asia, and Europe. The first participant was screened on 27 March 2013. The last study visit occurred on 18 July 2018.
| Milestone | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) |
|---|---|---|
| Started | 246 | 6 |
| Completed | 215 | 6 |
| Not completed | 31 | 0 |
| Withdrew: Enrolled but not treated | 4 | 0 |
| Withdrew: Adverse event | 7 | 0 |
| Withdrew: Death | 3 | 0 |
| Withdrew: Investigator's discretion | 4 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrew consent | 5 | 0 |
| Withdrew: Lost to follow-up | 7 | 0 |
eGFR is a measurement of the kidney's ability to filter blood.
| mL/min | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) |
|---|---|---|
| Baseline | 55.6 (45.7 to 62.4) | 60.2 (45.0 to 63.2) |
| Change at Week 24 | -0.4 (-4.7 to 4.5) | -0.3 (-3.6 to 1.3) |
eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,cysC method is adjusted for age and sex.
| mL/min/1.73 m^2 | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) |
|---|---|---|
| Baseline | 69.7 (55.9 to 82.7) | 70.2 (64.0 to 100.8) |
| Change at Week 24 | 3.8 (-4.8 to 11.2) | 3.9 (-3.3 to 13.2) |
eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,creatinine method is adjusted for age, race, and sex.
| mL/min/1.73 m^2 | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) |
|---|---|---|
| Baseline | 54.1 (46.0 to 62.8) | 54.4 (41.7 to 81.4) |
| Change at Week 24 | -1.8 (-6.1 to 4.9) | -2.6 (-11.1 to -0.9) |
aGFR was directly measured using iohexol plasma clearance (CLiohexol).
| mL/min | Substudy Participants |
|---|---|
| Baseline | 60.1 ± 19.06 |
| Change at Week 2, 4, or 8 | -0.6 ± 8.45 |
| Change at Week 24 | 1.4 ± 9.91 |
CTX is a biomarker of bone turnover.
| percentage change | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) |
|---|---|---|
| Change at Week 24 | -3.9 (-15.8 to 10.7) | 16.9 (0.0 to 21.7) |
| Change at Week 48 | -2.2 (-16.7 to 24.4) | 0.0 (-4.8 to 10.8) |
P1NP is a biomarker of bone turnover.
| percentage change | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) |
|---|---|---|
| Change at Week 24 | -12.98 (-34.48 to 8.86) | 6.44 (-5.08 to 47.62) |
| Change at Week 48 | -25.29 (-45.98 to 2.00) | 2.27 (-29.12 to 41.80) |
Urine RBP is a renal biomarker which is used to evaluate drug-induced kidney injury.
| percentage change | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) |
|---|---|---|
| Change at Week 24 | -56.2 (-90.0 to -11.8) | 68.8 (-37.1 to 72.6) |
| Change at Week 48 | -68.9 (-92.2 to -20.5) | 47.8 (13.3 to 78.9) |
| Change at Week 96 | -64.1 (-91.4 to 9.8) | 55.0 (-10.5 to 197.0) |
| Change at Week 144 | -63.8 (-92.4 to 4.6) | -1.0 (-10.2 to 43.4) |
Urine beta-2-microglobulin is a renal biomarker which is used to evaluate drug-induced kidney injury.
| percentage change | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) |
|---|---|---|
| Change at Week 24 | -70.7 (-92.6 to -11.1) | -19.5 (-93.0 to 81.3) |
| Change at Week 48 | -76.5 (-94.6 to -17.7) | -59.2 (-85.0 to 34.3) |
| Change at Week 96 | -83.6 (-96.4 to -31.1) | -45.9 (-95.8 to 195.6) |
| Change at Week 144 | -81.9 (-95.5 to -18.0) | -3.6 (-66.7 to 73.5) |
Adverse events (AEs) and graded laboratory abnormalities occurring during the E/C/F/TAF treatment period were summarized across the participant population. A participant was counted once if they had a qualifying event.
| percentage of participants | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) |
|---|---|---|
| Any AE | 95.5 | 100.0 |
| Grade 3 or 4 AE | 22.3 | 16.7 |
| AE leading to drug discontinuation | 5.0 | 0 |
| Serious AE | 22.7 | 16.7 |
| Grade 3 or 4 laboratory abnormality | 42.6 | 66.7 |
The percentage of participants achieving HIV-1 RNA \< 50 Copies/mL at Weeks 24, 48, 96, and 144 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) |
|---|---|---|
| Week 24 | 95.0 | 83.3 |
| Week 48 | 93.0 | 100.0 |
| Week 96 | 88.4 | 100.0 |
| Week 144 | 81.4 | 100.0 |
Cmax is defined as the maximum concentration of drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
| ng/mL | Substudy Participants |
|---|---|
| Pharmacokinetic (PK) Parameter: Cmax of TAF | 269.8 ± 180.77 |
Tmax is defined as the time of Cmax. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
| hours | Substudy Participants |
|---|---|
| PK Parameter: Tmax of TAF | 0.97 (0.50 to 1.98) |
Clast is defined as the last observable concentration of drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
| ng/mL | Substudy Participants |
|---|---|
| PK Parameter: Clast of TAF | 7.6 ± 25.73 |
Tlast is defined as the time of Clast. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
| hours | Substudy Participants |
|---|---|
| PK Parameter: Tlast of TAF | 4.45 (3.82 to 5.00) |
λz is defined as the terminal elimination rate constant. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
| 1/hour | Substudy Participants |
|---|---|
| PK Parameter: λz of TAF | 1.764 ± 1.4521 |
AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
| ng*h/mL | Substudy Participants |
|---|---|
| PK Parameter: AUCtau of TAF | 368.4 ± 631.20 |
t1/2 is defined as the estimate of the terminal elimination half-life of the drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
| hours | Substudy Participants |
|---|---|
| PK Parameter: t1/2 of TAF | 0.43 (0.37 to 0.52) |
TFV-DP is an active phosphorylated metabolite of tenofovir alafenamide. AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). Blood draws for this outcome may have been at the Week 2, 4, or 8 visit.
| µmol*h/L | Substudy Participants |
|---|---|
| PK Parameter: AUCtau of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cell (PBMC) for Participants Enrolled in PK/PD Sub-study | 50.6 ± 55.75 |
eGFR is a measurement of the kidney's ability to filter blood.
| mL/min | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) |
|---|---|---|
| Baseline | 55.6 (45.7 to 62.4) | 60.2 (45.0 to 63.2) |
| Change at Week 48 | -0.6 (-5.4 to 5.4) | -0.6 (-1.9 to 4.2) |
| Change at Week 96 | 0.6 (-4.6 to 7.2) | -1.9 (-4.0 to 6.0) |
| Change at Week 144 | 1.5 (-4.8 to 7.2) | 7.0 (3.3 to 11.2) |
eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,cysC method is adjusted for age and sex.
| mL/min/1.73 m^2 | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) |
|---|---|---|
| Baseline | 69.7 (55.9 to 82.7) | 70.2 (64.0 to 100.8) |
| Change at Week 48 | 1.7 (-7.3 to 12.0) | 7.3 (-0.1 to 12.2) |
| Change at Week 96 | 3.2 (-3.6 to 11.8) | 5.6 (-7.2 to 20.8) |
| Change at Week 144 | 3.1 (-4.8 to 11.8) | 3.5 (-1.8 to 22.9) |
eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,creatinine method is adjusted for age, race, and sex.
| mL/min/1.73 m^2 | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) |
|---|---|---|
| Baseline | 54.1 (46.0 to 62.8) | 54.4 (41.7 to 81.4) |
| Change at Week 48 | -1.7 (-7.9 to 4.2) | -3.0 (-4.9 to 0.6) |
| Change at Week 96 | 0.1 (-5.7 to 6.4) | -3.1 (-9.5 to 2.1) |
| Change at Week 144 | 1.7 (-5.3 to 8.5) | 0.9 (-5.7 to 6.0) |
Collected over First dose date up to Week 240 plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (Treatment-experienced) | — | 55/242 (22.7%) | 195/242 (80.6%) |
| Cohort 2 (Treatment-naive) | — | 1/6 (16.7%) | 5/6 (83.3%) |
| Event | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) |
|---|---|---|
| Suicidal ideationPsychiatric disorders | 0/242 | 1/6 |
| Acute myocardial infarctionCardiac disorders | 4/242 | 0/6 |
| PneumoniaInfections and infestations | 4/242 | 0/6 |
| DehydrationMetabolism and nutrition disorders | 3/242 | 0/6 |
| Cardiac failure congestiveCardiac disorders | 2/242 | 0/6 |
| Abdominal painGastrointestinal disorders | 2/242 | 0/6 |
| BronchitisInfections and infestations | 2/242 | 0/6 |
| GastroenteritisInfections and infestations | 2/242 | 0/6 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 2/242 | 0/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/242 | 0/6 |
| Event | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) |
|---|---|---|
| HyperlipidaemiaMetabolism and nutrition disorders | 7/242 | 2/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 25/242 | 2/6 |
| Supraventricular extrasystolesCardiac disorders | 1/242 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 32/242 | 1/6 |
| Gingival painGastrointestinal disorders | 0/242 | 1/6 |
| Mouth ulcerationGastrointestinal disorders | 2/242 | 1/6 |
| Chest painGeneral disorders | 10/242 | 1/6 |
| FatigueGeneral disorders | 20/242 | 1/6 |
| Peripheral swellingGeneral disorders | 8/242 | 1/6 |
| BronchitisInfections and infestations | 37/242 | 1/6 |
Safety Analysis Set: participants were enrolled and received at least 1 dose of study drug
| Age, Continuous(years) | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) | Total |
|---|---|---|---|
| Mean | 58 ± 9.9 | 55 ± 7.1 | 58 ± 9.8 |
| Sex: Female, Male(Participants) | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) | Total |
|---|---|---|---|
| Female | 50 | 0 | 50 |
| Male | 192 | 6 | 198 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) | Total |
|---|---|---|---|
| Race — Asian | 34 | 1 | 35 |
| Race — American Indian or Alaska Native | 1 | 0 | 1 |
| Race — Black or African American | 44 | 3 | 47 |
| Race — Native Hawaiian or Pacific Islander | 2 | 0 | 2 |
| Race — White | 152 | 2 | 154 |
| Race — Other | 7 | 0 | 7 |
| Race — Not Permitted | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 31 | 1 | 32 |
| Ethnicity — Not Hispanic or Latino | 209 | 5 | 214 |
| Ethnicity — Not Permitted | 2 | 0 | 2 |
| Region of Enrollment(Participants) | Cohort 1 (Treatment-experienced) | Cohort 2 (Treatment-naive) | Total |
|---|---|---|---|
| United States | 166 | 5 | 171 |
| United Kingdom | 5 | 0 | 5 |
| Thailand | 30 | 1 | 31 |
| Spain | 13 | 0 | 13 |
| Netherlands | 2 | 0 | 2 |
| Dominican Republic | 6 | 0 | 6 |
| Mexico | 2 | 0 | 2 |
| Australia | 12 | 0 | 12 |
| France | 6 | 0 | 6 |
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Mar 2013 to primary completion in Jul 2014, 16 months.
Results were first posted in Feb 2016, 1 year 6 months after primary completion. A results delay was requested in Sep 2014.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 16 months is below that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide